CAS: 40499-83-0; Pyrrolidin-3-Ol

相似化合物

86070-82-8 100243-39-8 100858-32-0

上下游产品

CAS号51-35-4 L-羟脯氨酸 | CAS号95656-88-5 N-Cbz-3-羟基吡咯烷 | CAS号775-15-5 N-苄基-3-吡咯烷醇 | CAS号104641-60-3 (R)-(-)-1-甲基-3-羟基吡咯烷 | CAS号134002-25-8 3-(S)-(1-氨基甲酰-1... | CAS号100858-33-1 (|R|)-(-)-1-Cbz... | CAS号125787-05-5 1-Pyrrolidineca... | CAS号133034-00-1 1-(对甲苯磺酰)-(R)-(... | CAS号1187927-92-9 (S)-3-(4-FLUORO... | CAS号680223-71-6 1-Pyrrolidinepr...

N-苄基-3-吡咯烷醇置于palladium On Activated Charcoal 氢气,溶剂黄146体系中,20.0 °C,68.95 Kpa 条件下,反应 120.0H,以92%的收率获得产物3-羟基吡咯烷
参考文献:核碱基的外消旋和对映体3-吡咯烷基衍生物的合成
标题:核碱基的外消旋和对映体3-吡咯烷基衍生物的合成
摘要:描述了核碱基的新型3-吡咯烷基衍生物的合成.从苹果酸开始,我们改善了外消旋和光学活性的合成ñ-苄基-3-羟基吡咯烷-2,5-二酮类,其中转化在四个步骤进入ñ-叔丁氧基羰基-3-Mesyloxypyrrolidines,关键合成子为嘌呤和嘧啶核碱基的烷基化.嘌呤和嘧啶与钠盐的铯盐的烷基化ñ-叔丁氧基羰基-3-Mesyloxypyrrolidines顺利进行,得到9-取代的嘌呤衍生物和1-取代的嘧啶衍生物的中等产率的高收率.使用(S)-N-Tert-丁氧基羰基-3-甲氧基苯并吡咯烷作为合成两个对映体n-Boc-3-吡咯烷基亚基腺嘌呤的相同中间体,并考虑到产品的手性HPLC分析所获得的结果,我们证明了甲磺酰基基团的亲核取代反应通过转化和不保留配置.测试了制备的化合物的细胞抑制和抗病毒特性,但未发现明显的活性.
DOI:10.1016/j.Tet.2006.03.078

专利信息

专利号:US-7825244-B2
优先权日:2005-06-10
标题:Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
发明人：BAINDUR NAND; GAUL MICHAEL DAVID; KREUTTER KEVIN DOUGLAS; XU GUOZHANG
权利人:JANSSEN PHARMACEUTICA NV
摘要:The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula C: n nwherein R 1 , R 2 , R 99 , and X are as defined herein, the use of such compounds in the synthesis of protein tyrosine kinase inhibitors, particularly inhibitors of FLT3 and/or c-kit and/or TrkB.

专利号:WO-2025101716-A1
优先权日:2023-11-07
标题:Processes for synthesis of trifunctionalized sulfur(vi) compounds
发明人：LOPCHUK JUSTIN; SHULTZ ZACHARY; ATHAWALE PARESH
权利人:H LEE MOFFITT CANCER CT & RES
摘要:This disclosure describes processes for the asymmetric synthesis of trifunctionalized sulfur(VI) containing organic compounds of Formula I and Formula VI, as well as compounds of Formula I and Formula VI prepared by the processes described.

专利号:US-9758507-B2
优先权日:2010-07-01
标 题:Chiral synthesis of pyrrolidine core compounds en route to neuronal nitric oxide synthase inhibitors
发明人：SILVERMAN RICHARD B; XUE FENGTIAN
权利人:UNIV NORTHWESTERN
摘要:A chiral synthesis of pyrrolidine compounds en route to selective neuronal nitric oxide synthase inhibitors, and representative inhibitor compounds heretofore unattainable.

专利号:US-8557979-B2
优先权日:2004-06-10
标题 :Carbapenem antibacterials with gram-negative activity and processes for their preparation
发明人：CHOI WOO-BAEG; KOWALIK EWA
权利人:CHOI WOO-BAEG; KOWALIK EWA; FOB SYNTHESIS INC
摘要:The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment. The present invention is also in the field of synthetic organic chemistry and is specifically provides an improved method of synthesis of β-methyl carbapenems which are useful as antibacterial agents.

专利号:US-2004049049-A1
优先权日:2002-06-14
标 题 :Stereoselective synthesis of 1,2-disubstituted cycloalkyls
发明人：JURAYJ JURJUS F; FARHAN EMILE; SHARMA PRADEEP K
权利人:JOHNSON MATTHEY PHARMACEUTICAL
摘要:A stereoselectively method of preparing a 1,2-disubstituted cycloalkyl, such as aminocycloalkyl ether compounds, from a trans-1,2-disubstituted cycloalkyl or a cis-2-substituted cycloalkanol. For example, a stereoselective method of preparing 1R-(3R-hydroxypyrrolidin-1-yl)-2R-(2-phenylethoxy)-cyclohexane from 1R,2R-cyclohexanediol or from meso-cis-1,2-cyclohexanediol is described. Aminocycloalkyl ethers, such as 1R-(3R-hydroxypyrrolidin-1-yl)-2R-(2-phenylethoxy)-cyclohexane, can be used to treat cardiac disease.

专利号:US-2024287084-A1
优先权日:2021-10-28
标 题 :Synthesis of [1,2,3]triazolo[4,5-d]pyrimidines
发明人：ADAM JEAN-MICHEL; GRETHER UWE; MOESSNER CHRISTIAN; TOSATTI PAOLO
权利人:HOFFMANN LA ROCHE
摘要:The present invention relates to a process for the preparation of [1,2,3]triazolo[4,5-d]pyrimidine derivatives useful as pharmaceutically active compounds, in particular 1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol.